Cut Stack Research Protocol: Test Propionate + Tren Ace + Masteron

Research Disclaimer: All compounds described are sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.

The "cut stack" is the best-characterized three-compound injectable anabolic research combination: testosterone propionate (TP), trenbolone acetate (TrA), and drostanolone propionate (DP). Each component uses a short (propionate/acetate) ester for rapid kinetics and precise dosing control. Pharmacologically, the three compounds are selected for complementary mechanisms: TP provides testosterone baseline and AR agonism; TrA provides extreme anabolic:androgenic ratio, GR antagonism, and nutrient partitioning; DP provides anti-estrogenic AR activity and SHBG displacement. Together they are used in body composition research — specifically fat-free mass preservation during caloric restriction — with the pharmacological rationale for each component well-characterized.

Table of Contents#

1. Pharmacological Rationale: Why These Three Compounds
2. Component Pharmacokinetics Summary
3. Mechanism Matrix: What Each Compound Does
4. Combined Pharmacodynamics
5. Endpoint Selection for Body Composition Research
6. Pre-Mixed Cut Stack Formulations
7. Research Protocol Design
8. Key References

Pharmacological Rationale: Why These Three Compounds#

The design principle of the cut stack:

Why short esters?

• Propionate (3C) and acetate (2C): t½ ~1.5–2.5 days vs. enanthate (7C) t½ ~7–10 days
• For research: rapid wash-in and wash-out → better temporal control over hormone levels
• Easier dose modification mid-protocol
• Faster recovery of endogenous hormone axis post-protocol
• Trade-off: more frequent injections (EOD) vs. longer esters (1–2× weekly)

Component Pharmacokinetics Summary#

Combined protocol injection schedule:

• Because all three compounds use propionate/acetate esters with similar t½, they can be co-injected every other day (EOD) in the same syringe (if solvent-compatible)
• Pre-mixed formulations available (150–200 mg/mL total, oil-based)

Mechanism Matrix: What Each Compound Does#

Testosterone propionate#

• AR agonist: maintains lean mass signal
• Aromatizes → E2: NECESSARY at baseline (bone, cardiovascular, libido signaling)
• 5α-reduces → DHT: androgenic effects in skin/scalp/prostate
• Reference hormone: allows proper quantification of added effects from TrA and DP

Trenbolone acetate#

• Extreme AR affinity (Kd ~0.2 nM, ~5–8× testosterone)
• GR partial antagonist → blocks GR-driven muscle catabolism (MAFbx/MuRF-1 suppression) → anti-catabolic under caloric restriction
• No aromatization → no additional E2 burden
• mTOR pathway activation → enhanced protein synthesis
• Nutrient partitioning: AR activation in adipocytes → increased lipolysis, reduced lipogenesis

Drostanolone propionate#

• AR activation with anti-estrogenic side effect profile
• Partial ER antagonism → competes with E2 → reduces E2 transcriptional activity
• SHBG displacement → increases free fraction of co-administered testosterone
• No aromatization → anti-estrogenic contribution to the stack
• SHBG displacement specifically: drostanolone's high SHBG affinity → more bioavailable testosterone per mg administered

Combined Pharmacodynamics#

AR occupancy additive:

• Three separate AR agonists → AR occupancy approaches saturation → maximum possible AR-mediated anabolic signal
• AR target tissue kinetics: multiple AR agonists → prolonged nuclear AR residence → more sustained target gene transcription

Estrogenic management:

• Only testosterone contributes E2 via aromatization
• Drostanolone partially antagonizes E2 at ER level
• Net: lower estrogenic effect per unit AR stimulation than testosterone alone

Anti-catabolic synergy:

• Trenbolone GR antagonism → blocks glucocorticoid-driven catabolism (atrogin-1/MuRF-1)
• Testosterone AR agonism → blocks FOXO3a → reduces atrogin-1 transcription independently
• Combined: two independent anti-catabolic pathways activated → particularly relevant under caloric restriction (when endogenous cortisol rises)

SHBG displacement cascade:

• Drostanolone → occupies SHBG → releases bound testosterone
• More free testosterone → more AR activation → more anabolic signal per unit testosterone dose

Endpoint Selection for Body Composition Research#

Primary endpoints (castrated rat model):

• Body composition via DEXA: lean mass, fat mass, bone mineral density
• Tissue weights: levator ani (anabolic marker), ventral prostate (androgenic marker) → A:A calculation
• Serum: E2, testosterone (LC-MS/MS), SHBG, LH, FSH

Metabolism endpoints:

• Energy expenditure (indirect calorimetry or metabolic cage)
• Adipose lipolysis: serum NEFA, adipose CPT1/HSL expression (RT-qPCR)
• Hepatic lipid: liver TG content (histology + enzymatic assay)

Anti-catabolic endpoints (caloric restriction model):

• Muscle ubiquitin-proteasome: atrogin-1, MuRF-1 mRNA (RT-qPCR)
• Protein synthesis rate: SUnSET method (puromycin incorporation)
• Muscle fiber cross-sectional area (Type I/II): histology with ATPase/myosin staining

Safety endpoints:

• Hematocrit (TrA → EPO → polycythemia risk)
• Liver enzymes (ALT/AST — no C17α-alkylated compound in this stack, but monitoring still warranted)
• Cardiovascular: cardiac mass (cardiomegaly at high TrA doses), blood pressure

Pre-Mixed Cut Stack Formulations#

Some research suppliers offer pre-mixed cut stack solutions:

Typical composition:

• Testosterone propionate: 50–100 mg/mL
• Trenbolone acetate: 50–75 mg/mL
• Drostanolone propionate: 50–100 mg/mL
• In pharmaceutical-grade oil (MCT or benzyl benzoate/benzyl alcohol)

Research considerations:

• Pre-mixed formulations: convenient but fixed ratio — limits dose adjustments per component
• Separate vials: allow precise individual titration (preferred for mechanistic research)
• Stability: acetate/propionate esters stable at room temperature up to 24 months in sealed vials; avoid freeze-thaw cycling

Research Protocol Design#

Cut stack body composition study: castrated rat model#

Key References#

1. Bhasin S, et al. (2001). "Testosterone dose-response relationships in healthy young men." American Journal of Physiology, 281(6):E1172–E1181.

2. Brower KJ. (2002). "Anabolic steroids: addictive, psychiatric, and medical consequences." American Journal of Addictions, 11(4):253–259.

3. Wood RI. (2008). "Anabolic-androgenic steroid dependence? Insights from animals and humans." Frontiers in Neuroendocrinology, 29(4):490–506.

Research Use Only: All compounds described are sold exclusively for in-vitro research and laboratory use. Not for unsupervised use. JuicedPharma does not provide medical advice.

Published by JuicedPharma Research Team · September 2026 · Category: Research Protocols & Science